Movers roundup: CapitalSource, Immunomedics

By Associated Press April 15, 2008 Comments (0)

0 Recommendations

Among the stock activity stories for Tuesday, April 15, from AP Financial News:

NEW YORK (AP) _ Shares of CapitalSource Inc. fell Tuesday, after a handful of analysts said the company still faces a number of challenges despite an increase in funding from a recent acquisition.

NEW YORK (AP) _ Immunomedics stock is rising after the biopharmaceutical company said its drug milatuzumab was effective in a preclinical trial, extending the survival of mice with a blood cancer.

NEW YORK (AP) _ Shares of Diamond Offshore Drilling Inc. fell Tuesday after an analyst cut his earnings estimate for the company because of unscheduled downtime and a $6.2 million contract dispute.

NEW YORK (AP) _ Shares of Infosys Technologies Ltd. gained sharply Tuesday after analysts were comforted by the Indian information-technology company's fourth-quarter profits.

Comments (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment icon found on every comment.

Be the first one to comment on this article.

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Compare Brokers

DocumentId: 621671, ~/articles/articlehandler.aspx, 7/24/2008 3:22:30 PM,

Sign up for FREE Motley Fool site access!

Already registered? Login Here

It’s FREE! Enter your email address, and we’ll rush you to the article you're looking for right now.

Privacy / Legal Information

We will use your email address only to keep you informed about updates to our web site and about other products and services that we think might interest you. The Motley Fool respects your privacy. Please read our Privacy Statement